VTRS Chart

1 Month

	Date	Diff
	2025-03-31	+0.35 %
Opus Genetics, Inc. has announced significant advancements in its gene therapy programs and financial stability after raising $21.5 million, which has positively impacted its stock performance, contributing to a 0.35% increase in Viatris (VTRS) stock likely due to investor confidence from the company's promising pipeline and strategic actions.
	2025-03-27	-1.34 %
Viatris (VTRS) stock fell by 1.34% as part of the ongoing fallout from a significant decline in its stock price following disappointing fourth quarter and full year 2024 financial results, lower-than-expected guidance for 2025, and concerns related to its manufacturing facility in India, which led to an investigation for potential securities fraud. Viatris (VTRS) stock fell by 1.34% amid an ongoing investigation by Rosen Law Firm into potential misleading business information provided by the company, which first triggered a larger drop of 15.2% following the announcement of a warning letter from the FDA that could negatively impact its revenues by approximately $500 million in 2025.
	2025-03-21	-3.07 %
Viatris (VTRS) stock fell by -3.07% due to shareholder concerns over the company's strategic missteps and governance failures exemplified by a recent dilutive financing that undermines existing stockholder interests, as highlighted by the Restore Value Slate's push for new board leadership ahead of the upcoming Annual Meeting.
	2025-03-20	+0.21 %
The article discusses an investigation initiated by Rosen Law Firm into potential securities claims against Viatris Inc. (NASDAQ: VTRS) due to allegations of misleading business information which may have impacted shareholder value, following a significant drop in stock price earlier this year. The slight increase of 0.21% in Viatris (VTRS) stock could be attributed to a potential stabilization in market sentiment as investors weigh the ongoing legal developments and the company's adjustments in response to regulatory challenges, despite previous declines following the FDA warnings.
	2025-03-19	-1.05 %
The article discusses that Viatris (VTRS) stock experienced a decline of 1.05% following an investigation announcement by Faruqi & Faruqi, LLP, after the company reported disappointing fourth-quarter financial results and lower-than-expected guidance for 2025, alongside ongoing remediation issues at a manufacturing facility.
	2025-03-05	+1.17 %
The article reports that Viatris (VTRS) stock experienced a 1.17% increase following a significant decline after disappointing financial results and lower guidance, as investors may be reassessing the company's potential recovery, particularly in light of ongoing remediation efforts at its manufacturing facility in India. Viatris (VTRS) stock rose by 1.17% likely due to positive market sentiment surrounding the pharmaceutical sector's potential growth from upcoming biosimilars, despite concerns over the impact of steep US tariffs on drug prices and patient access.
	2025-02-28	-3.15 %
Viatris (VTRS) stock fell by 3.15% due to concerns surrounding its recent agreements for developing cenerimod, a new drug candidate for autoimmune diseases, which may have uncertainties related to regulatory approvals and market potential.
	2025-02-27	-15.21 %
Viatris (VTRS) stock experienced a significant decline of -15.21%, primarily due to disappointing earnings results and heightened investor concerns about future growth prospects amid competitive pressures and market volatility. The article discusses the significant 15.21% decline in Viatris (VTRS) stock, likely attributed to negative investor sentiment amidst broader market volatility and uncertainties impacting the healthcare sector.
	2025-01-16	-0.44 %
Viatris Inc. (NASDAQ:VTRS) saw a 2.82% decline in its stock price, closing at $11.39, due to investor sell-off triggered by analyst comments about the stock entering oversold territory, compounded by negative sentiment surrounding the planned closure of its manufacturing plant in Ireland.
	2025-01-06	-2.69 %
Viatris (VTRS) stock went down by -2.69% likely due to concerns surrounding medication shortages and regulatory challenges impacting the pharmaceutical sector, particularly in the diabetes treatment market.
	2024-12-24	-0.72 %
Viatris (VTRS) stock fell by 0.72% amid scrutiny over a judge’s financial ties to the healthcare industry, raising concerns about potential conflicts of interest in a high-profile case involving healthcare criticism. The decline is likely influenced by the controversy surrounding the judge's investments, reflecting broader concerns about integrity and the healthcare sector. Viatris (VTRS) stock declined by 0.72% due to concerns over potential conflicts of interest involving the judge overseeing a high-profile case related to the shooting of UnitedHealthcare’s CEO, which has sparked scrutiny of the pharmaceutical industry.
	2024-11-29	-0.98 %
Viatris (VTRS) stock experienced a decline of 0.98% due to a challenging market environment and competition from other pharmaceutical companies, as highlighted by comparative analyses between Revance Therapeutics and AstraZeneca, where the latter showed stronger revenues and earnings.
	2024-11-07	+13.52 %
Viatris (VTRS) stock surged by 13.52% due to positive market sentiment and investor confidence amidst broader stock market fluctuations and forthcoming corporate developments. The increase in Viatris stock can be attributed to favorable market perceptions and potential growth factors regarding the company's operations and strategic direction.
	2024-10-28	+2.8 %
Viatris (VTRS) stock rose 2.8% due to factors such as strong institutional ownership indicating confidence from large investors, and its collaboration with Revance Therapeutics, which is advancing in various drug developments, potentially enhancing future growth prospects.
	2024-10-15	+3.95 %
Viatris (VTRS) stock rose by 3.95% likely due to speculation surrounding a potential favorable regulatory environment for cryptocurrencies if former President Donald Trump wins the upcoming presidential election, which may influence investor sentiment positively towards companies linked to the digital asset sector.
	2024-10-07	-2.24 %
Viatris (VTRS) stock fell by 2.24% due to the recall of specific batches of the blood pressure medication trandolapril after tests revealed variability in its content, leading to concerns around the product's reliability.